X0508 4 2024-07-22 true 0001817241 Artiva Biotherapeutics, Inc. ARTV 0001739920 venBio Global Strategic Fund III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869303 VENBIO GLOBAL STRATEGIC GP III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869300 VENBIO GLOBAL STRATEGIC GP III, LTD 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001329161 Adelman Robert J 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001278411 GOODMAN COREY S 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true false Common Stock 2024-07-22 4 C 0 843592 A 843592 D Common Stock 2024-07-22 4 C 0 214692 A 1058284 D Common Stock 2024-07-22 4 J 0 461687 A 1519971 D Common Stock 2024-07-22 4 P 0 416666 12 A 1936637 D Series A Convertible Preferred Stock 2024-07-22 4 C 0 843592 D Common Stock 843592 0 D Series B Convertible Preferred Stock 2024-07-22 4 C 0 214692 D Common Stock 214692 0 D Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein. Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20. Dr. Aaron Royston is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III. venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ Antoinette Delhonte, as attorney-in-fact 2024-07-22 venBio Global Strategic GP III, L.P., by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ Antoinette Delhonte, as attorney-in-fact 2024-07-22 venBio Global Strategic GP III, Ltd., by: /s/ Antoinette Delhonte, as attorney-in-fact 2024-07-22 Robert Adelman, by: /s/ Antoinette Delhonte, as attorney-in-fact 2024-07-22 Corey Goodman, by: /s/ Antoinette Delhonte, as attorney-in-fact 2024-07-22